Dominari (DOMH) Projected to Post Earnings on Monday

Dominari (NASDAQ:DOMH) is expected to be issuing its results before the market opens on Monday, March 30th. Analysts expect the company to announce earnings of ($0.17) per share and revenue of $56.82 million for the quarter.

Dominari Stock Down 1.9%

Shares of DOMH stock opened at $3.10 on Friday. Dominari has a 12 month low of $2.76 and a 12 month high of $8.40. The company has a market cap of $50.28 million, a PE ratio of 0.56 and a beta of 0.83. The business’s 50 day moving average is $3.47 and its two-hundred day moving average is $4.66.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings downgraded shares of Dominari from a “hold (c-)” rating to a “sell (d+)” rating in a report on Monday, January 12th. One research analyst has rated the stock with a Sell rating, According to MarketBeat, the stock currently has a consensus rating of “Sell”.

Institutional Trading of Dominari

Hedge funds have recently added to or reduced their stakes in the business. Millennium Management LLC bought a new position in Dominari in the 3rd quarter worth approximately $213,000. NewEdge Advisors LLC acquired a new stake in shares of Dominari in the fourth quarter worth $50,000. Renaissance Technologies LLC acquired a new stake in shares of Dominari in the fourth quarter worth $412,000. Vanguard Group Inc. increased its position in Dominari by 8.0% during the third quarter. Vanguard Group Inc. now owns 345,896 shares of the company’s stock worth $2,452,000 after acquiring an additional 25,694 shares during the period. Finally, Connective Capital Management LLC raised its stake in Dominari by 26.2% during the 3rd quarter. Connective Capital Management LLC now owns 335,273 shares of the company’s stock valued at $2,377,000 after purchasing an additional 69,545 shares during the last quarter. Institutional investors own 42.48% of the company’s stock.

About Dominari

Dominari Holdings Inc, a biotechnology company, focuses on developing small-molecule anticancer therapeutics. The company's pipeline of therapeutics includes therapies for prostate cancer, pancreatic cancer, acute myeloid leukemia (AML), and acute lymphoblastic leukemia. It is developing DHA-dFdC, a pancreatic drug candidate; and KPC34, a small molecule treatment for acute myeloid leukemia and acute lymphoblastic leukemia. The company is also developing an antiviral platform that inhibits replication of viruses, including influenza virus, Ebolavirus and Marburg virus, SARS-CoV, MERS-CoV, and SARS-CoV-2.